ARS Pharmaceuticals Prepares for Major Investor Engagement
ARS Pharmaceuticals, Inc., a dynamic biopharmaceutical company focused on creating products for patients at risk of severe allergic reactions, is gearing up for significant investor conferences. The company, recognized for its groundbreaking solutions, especially the epinephrine nasal spray neffy, will participate in two pivotal events this September.
What to Expect at Upcoming Conferences
Richard Lowenthal, the Co-Founder, President, and CEO of ARS Pharmaceuticals, along with Eric Karas, the Chief Commercial Officer, will be at the forefront of these presentations. Their involvement at the Cantor Global Healthcare Conference and the Stifel Immunology and Inflammation Summit will lay out the incredible potential of their innovative products and strategies.
Cantor Global Healthcare Conference Details
The first engagement will take place at the Cantor Global Healthcare Conference. The presentation will be in the form of a fireside chat scheduled for Wednesday, September 3, 2025, at 3:55 p.m. ET. This event will take place in New York and aims to highlight the company’s path to empowering patients facing allergy challenges.
Stifel Immunology and Inflammation Summit Overview
Next on the agenda is the Stifel Immunology and Inflammation Summit, set for Monday, September 15, 2025, at 12:00 p.m. ET. This virtual presentation is expected to delve into ARS Pharmaceuticals' mission to make severe allergy treatment more accessible and effective for those who need it the most.
How to Access the Presentations
For those interested in benefiting from these insights, live webcasts of both presentations will be available, and recordings will be accessible for 30 days post-event. Attendees can visit the Events & Presentations section on ARS Pharmaceuticals' website for more details.
About ARS Pharmaceuticals and Product Offering
ARS Pharmaceuticals is not just a name in the biopharmaceutical industry; it’s a lifeline for many at-risk individuals. Their flagship product, neffy, is an epinephrine nasal spray designed for emergency treatment of severe allergic reactions. This innovative product is available in the U.S. for individuals 4 years of age and older who weigh at least 33 lbs, providing a vital resource for emergency situations. In the EU, neffy caters to needs similar to those in the U.S. but includes indications for various allergens and circumstances.
Investor Relations and Contact Information
For investor-related inquiries, you can reach out to Justin Chakma at ARS Pharmaceuticals anytime. They are committed to fostering strong investor relations and providing updates that matter to their stakeholders.
Investor Contact:
Justin Chakma, ARS Pharma
justinc@ars-pharma.com
Frequently Asked Questions
1. What is ARS Pharmaceuticals focusing on at the upcoming conferences?
ARS Pharmaceuticals will present their innovative treatment options for patients at risk of anaphylaxis and discuss their growth strategies.
2. When is ARS Pharmaceuticals scheduled to present at the Cantor Conference?
The presentation is scheduled for September 3, 2025, at 3:55 p.m. ET in New York.
3. What is the product neffy?
neffy is an epinephrine nasal spray aimed at treating severe allergic reactions, making it easier for patients to access critical treatment quickly.
4. How can investors access the conference presentations?
Investors can access live webcasts and recorded sessions on the Events & Presentations page of ARS Pharmaceuticals' website following the events.
5. Who can be contacted for more information about the company?
For inquiries, investors can contact Justin Chakma at ARS Pharmaceuticals via email.
